Superluminal Medicines Raises $60M Series B Led by BVF Partners

Superluminal Medicines Closes $60M Series B

Superluminal Medicines, a Boston-based biotechnology company, has raised a $60 million Series B round. The financing was led by BVF Partners, with participation from Gaingels, Perceptive Advisors, NVentures, Cooley LLP, RA Capital Management, Deep Track Capital, Eli Lilly and Company, Insight Partners, and Catalio Capital Management.

The round was announced on September 3, 2026, and brings the company's funding stage to Series B.

What Superluminal Medicines Does

Superluminal Medicines integrates AI/ML, protein dynamics, and structural biology to discover small-molecule drugs against hard-to-drug G protein-coupled receptor (GPCR) targets. Its platform pairs Agentic Cryo-EM structure generation with machine-learning design and predictive ADME/toxicology models.

GPCRs remain one of the most commercially validated target classes in medicine, yet many members of the family have historically resisted small-molecule intervention. Superluminal's approach is aimed squarely at that gap, combining structural insight with computational design to expand the set of addressable GPCR targets.

Lead Program: MC4R Agonist for Rare Obesity

The company's wholly owned lead program is a selective, biased MC4R agonist targeting rare genetic forms of obesity and hypothalamic obesity. Superluminal expects the program to enter Phase 1 trials by the end of 2026.

The MC4R pathway is central to energy homeostasis, and rare genetic forms of obesity linked to this pathway represent a well-defined patient population. A selective, biased agonist approach is intended to engage the target with a specific signaling profile.

Pharma Collaborations

Beyond its internal pipeline, Superluminal advances pharma collaborations, including a partnership with Eli Lilly and Company on small-molecule GPCR programs for cardiometabolic diseases and obesity. Lilly's participation in the Series B is notable given that existing collaboration.

Investor Syndicate

The Series B syndicate combines specialist life-science investors and strategic participation:

• Lead: BVF Partners
• Participants: Gaingels, Perceptive Advisors, NVentures, Cooley LLP, RA Capital Management, Deep Track Capital, Eli Lilly and Company, Insight Partners, Catalio Capital Management

The mix spans crossover funds, venture investors, and a strategic pharmaceutical partner — a profile that supports both clinical advancement and continued platform development.

Why This Round Matters

Superluminal sits at the intersection of two active areas of biotech investment: AI-driven drug discovery and obesity therapeutics. The company's platform is designed to generate structural data on difficult GPCR targets and translate that into small-molecule candidates, while its lead asset targets a rare and genetically defined obesity population.

With the Series B in place, the stated near-term milestone is the transition of the MC4R agonist program into Phase 1 by the end of 2026. The company also continues to pursue partnered GPCR programs in cardiometabolic disease and obesity.

At a Glance

• Company: Superluminal Medicines
• Headquarters: Boston
• Round: Series B
• Amount: $60 million
• Announced: September 3, 2026
• Lead Investor: BVF Partners
• Focus: AI/ML-enabled small-molecule discovery against hard-to-drug GPCR targets
• Lead Program: Selective, biased MC4R agonist for rare genetic and hypothalamic obesity; Phase 1 expected by end of 2026
• Collaboration: Eli Lilly and Company on small-molecule GPCR programs for cardiometabolic diseases and obesity